Novo Nordisk
Novo Nordisk Finance Netherlands BV operates as a specialized financing subsidiary and debt issuing vehicle for Novo Nordisk A/S, the Danish global healthcare company. The operating parent discovers, develops, manufactures, and markets biological medicines for diabetes care, obesity management, hemophilia, and rare endocrine disorders under brands including Ozempic, Wegovy, and Victoza. Principal revenues and cash flows of the issuing vehicle derive from intercompany loan servicing, internal financing fees, and debt issuances guaranteed by Novo Nordisk A/S. Core end markets encompass healthcare systems, specialty pharmacies, hospital networks, and prescription patients globally through the parent company's commercial footprint. Positioned as a dedicated international financing vehicle, it supports capital structure management and global manufacturing facility expansion for Novo Nordisk. The company is incorporated and headquartered in Amsterdam, Netherlands, operating as a private subsidiary.
207 of the funds FundTelligence covers report a position in Novo Nordisk.
- Legal name
- NOVO NORDISK A/S
- Sector
- Health Care
- Country
- Denmark
- Funds holding it
- 207
- Exposure themes
- Incretin & GLP-1 Therapies, Obesity, Obesity & Metabolic Health
Funds holding Novo Nordisk
- Nordnet Danmark Indeks — Nordnet · 12.73 % (full portfolio disclosed, October 2026)
- C WorldWide Norden — C WorldWide · 9.9 % (largest positions only, October 2026)
- SEB Nordenfond — SEB · 9.78 % (full portfolio disclosed, June 2026)
- KLP AksjeNorden Mer Samfunnsansvar — KLP · 9.0 % (full portfolio disclosed, June 2026)
- KLP AksjeNorden Indeks — KLP · 8.53 % (full portfolio disclosed, June 2026)
- Nordea Nordic Sustainable Stars — Nordea Funds · 8.43 % (full portfolio disclosed, September 2026)
- Nordea Nordic Equity — Nordea Funds · 8.18 % (full portfolio disclosed, September 2026)
- Vibrand Norden — Vibrand · 8.05 % (full portfolio disclosed, June 2026)
Showing the 8 largest of 207 funds holding it.